financetom
Business
financetom
/
Business
/
Industrial equipment maker Hillenbrand's Q4 adjusted EPS beats estimates, helped by pricing strength
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Industrial equipment maker Hillenbrand's Q4 adjusted EPS beats estimates, helped by pricing strength
Nov 19, 2025 1:50 PM

Overview

* Hillenbrand ( HI ) fiscal Q4 net revenue falls 22% yr/yr due to MIME divestiture

* Adjusted EPS for fiscal Q4 beats consensus, despite a 18% yr/yr decline

* Company in October had agreed to be acquired by Lone Star in $3.8 bln all-cash deal

Outlook

* Hillenbrand ( HI ) will not provide fiscal year 2026 guidance due to pending acquisition

* Company expects acquisition by Lone Star to close by Q1 2026

Result Drivers

* MIME DIVESTITURE - Revenue and adjusted EBITDA decline primarily due to divestiture of MIME business

* LOWER VOLUME - Decreased capital equipment and aftermarket parts volumes contributed to revenue decline

* FAVORABLE PRICING - Pricing improvements helped offset some negative impacts from lower volume and cost inflation

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 $652 mln

Revenue

Q4 Beat $0.83 $0.61 (3

Adjusted Analysts

EPS )

Q4 Net $76 mln

Income

Q4 Beat $108 mln $96.77

Adjusted mln (3

EBITDA Analysts

)

Q4 18.60%

Adjusted

EBITDA

Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the industrial machinery & equipment peer group is "buy."

* Wall Street's median 12-month price target for Hillenbrand Inc ( HI ) is $32.00, about 1.2% above its November 18 closing price of $31.62

* The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 9 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact [email protected].

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Infleqtion and Churchill Capital Corp X Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Infleqtion and Churchill Capital Corp X Announce Confidential Submission of Draft Registration Statement on Form S-4 in Connection with Proposed Business Combination
Nov 4, 2025
BOULDER, Colo. & NEW YORK--(BUSINESS WIRE)-- Infleqtion, a global leader in neutral-atom–based quantum technology, and Churchill Capital Corp X ( CCCX ) , a publicly traded special purpose acquisition company, today announced the confidential submission of a draft registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) on October 29, 2025. The submission...
Equitable Holdings Q3 EPS misses estimates
Equitable Holdings Q3 EPS misses estimates
Nov 4, 2025
Overview * Equitable Holdings ( EQH ) reports Q3 net loss of $1.3 bln due to life reinsurance impact * Adjusted EPS for Q3 misses analyst expectations * Assets under management rose 7% yr/yr to $1.1 trillion Outlook * Equitable Holdings ( EQH ) maintains confidence in achieving 2027 financial targets * Company plans $1.5 bln capital deployment for growth...
Astronics Q3 sales miss estimates
Astronics Q3 sales miss estimates
Nov 4, 2025
Overview * Astronics ( ATRO ) Q3 sales up 3.8% to $211.4 mln, missing analyst expectations * Company reports Q3 net loss of $11.1 mln due to refinancing-related charges * Adjusted EBITDA for Q3 was $32.7 mln, or 15.5% of sales Outlook * Company expects Q4 revenue between $225 mln and $235 mln * Astronics ( ATRO ) sees 2025...
Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance 
Niagen Bioscience Q3 sales beat estimates on strong e-commerce performance 
Nov 4, 2025
Overview * Niagen Bioscience ( NAGE ) Q3 net sales rise 33%, beating analyst expectations * Adjusted EBITDA for Q3 increases 120%, reflecting improved operational performance * Company reaffirms full-year net sales growth outlook of 25% to 30% Outlook * Niagen Bioscience ( NAGE ) reaffirms 2025 net sales growth of 25% to 30% y-o-y * Company expects 2025 gross...
Copyright 2023-2026 - www.financetom.com All Rights Reserved